Tuesday, November 20, 2018 7:36:55 AM
PR NEWSWIRE 6:30 AM ET 11/20/2018
Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering
TORONTO and CAMBRIDGE, MA, Nov. 20, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc.(ARFXF) ; , a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today issued a narrated year-to-date overview and outlook on priorities for advancing its antibody programs targeting Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The presentation is available on the company website at https://bit.ly/2Ts1pk2
In this presentation, Dr. Elliot Goldstein, ProMIS President and CEO, discusses progress to date and priorities for future development.
Based on results of prior clinical trials targeting amyloid beta in AD and years of scientific research, there is a growing body of evidence that the optimum profile for a successful disease modifying therapy should be to selectively target the toxic, low molecular weight oligomers of amyloid beta.
Results of preclinical studies announced earlier this year clearly showed that PMN310, our lead therapeutic antibody for AD, selectively targets human toxic oligomers from AD patients.
"In our planned first clinical trial we look forward to evaluating this 'best in class' product profile with an innovative clinical trial design using emerging biomarkers that may indicate early signs of efficacy. Our goal is to generate initial clinical results by end of 2020", stated Dr. Goldstein.
Over the course of the year, ProMIS has made considerable progress in expanding its portfolio of opportunities across multiple neurodegenerative diseases. Using its unique discovery platform, ProMIS is developing and validating therapeutic antibodies for Parkinson's disease, targeting toxic oligomers of alpha-synuclein. Therapeutic antibodies are also under development for ALS, selectively targeting toxic aggregates of Tar-DNA binding protein (TDP43). ProMIS also recently announced discovery of novel therapeutic targets on tau protein implicated in the development of AD and other dementias.
"Based on interactions with potential pharmaceutical partners, we believe our proprietary discovery platform and the resulting expanded portfolio offer real partnering opportunities. Antibody therapeutics targeting toxic forms of tau, TDP43 and, especially alpha-synuclein, are high on the list of partnering objectives for many companies in the field. We are actively pursuing partnering discussions for our developing portfolio as we continue to generate data in support of these programs", stated Dr. Goldstein.
Both the narrated overview and related transcript can be accessed directly on the ProMIS Neurosciences(ARFXF) website, or at
https://bit.ly/2Ts1pk2
About ProMIS Neurosciences(ARFXF)
ProMIS Neurosciences, Inc. (ARFXF) is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences(ARFXF), please consult the Company's website at: www.promisneurosciences.com
Recent PMN News
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- ProMIS Neurosciences Issues Letter to Shareholders • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- ProMIS Neurosciences, Inc. Announces Leadership Transition • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- ProMIS Neurosciences Announces Publication on Novel Target for ALS • GlobeNewswire Inc. • 12/20/2023 12:00:00 PM
- ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease • GlobeNewswire Inc. • 11/20/2023 12:00:00 PM
- ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- ProMIS Neurosciences Closes $20.4 Million Private Placement Financing • GlobeNewswire Inc. • 09/08/2023 11:00:00 AM
- ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 04:18:53 PM
- ProMIS Neurosciences Announces $20.4 Million Private Placement Financing • GlobeNewswire Inc. • 08/21/2023 08:12:03 PM
- ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/14/2023 09:33:19 PM
- ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline • GlobeNewswire Inc. • 07/17/2023 11:00:00 AM
- ProMIS Announces Completion of Continuance • GlobeNewswire Inc. • 07/14/2023 11:45:00 AM
- ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange • GlobeNewswire Inc. • 07/10/2023 11:55:00 AM
- ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved • GlobeNewswire Inc. • 06/30/2023 12:00:00 PM
- Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time • GlobeNewswire Inc. • 06/29/2023 12:00:00 PM
- ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/15/2023 09:00:00 PM
- ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease • GlobeNewswire Inc. • 05/08/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM